|
1
|
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
|
Lancet
|
2001
|
3.60
|
|
2
|
Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function.
|
Diabetologia
|
2011
|
1.85
|
|
3
|
Overweight, obesity, and blood pressure: the effects of modest weight reduction.
|
Obes Res
|
2000
|
1.78
|
|
4
|
Human leptin: from an adipocyte hormone to an endocrine mediator.
|
Eur J Endocrinol
|
2000
|
1.53
|
|
5
|
Obesity, haemostasis and the fibrinolytic system.
|
Obes Rev
|
2002
|
1.40
|
|
6
|
Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome.
|
Int J Obes (Lond)
|
2006
|
1.22
|
|
7
|
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
|
Diabetes Obes Metab
|
2012
|
1.19
|
|
8
|
Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion.
|
Horm Metab Res
|
2003
|
1.06
|
|
9
|
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
|
Diabetes Obes Metab
|
2003
|
1.04
|
|
10
|
Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women.
|
Int J Obes Relat Metab Disord
|
2001
|
1.00
|
|
11
|
High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry.
|
J Clin Endocrinol Metab
|
1999
|
0.98
|
|
12
|
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
|
Rev Med Liege
|
2010
|
0.95
|
|
13
|
Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications.
|
Diabetes Metab
|
2004
|
0.92
|
|
14
|
Diabetic ketoacidosis-induced hyperkalemia. Prevalence and possible origin.
|
Intensive Care Med
|
1986
|
0.90
|
|
15
|
Hemoperfusion-hemodialysis ineffective for paraquat removal in life-threatening poisoning?
|
J Toxicol Clin Toxicol
|
1985
|
0.89
|
|
16
|
Helicobacter pylori, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus.
|
Aliment Pharmacol Ther
|
2002
|
0.87
|
|
17
|
Anthropometric and calorimetric evidence for the protein sparing effects of a new protein supplemented low calorie preparation.
|
Am J Clin Nutr
|
1985
|
0.84
|
|
18
|
Genetic association between WNT10B polymorphisms and obesity in a Belgian case-control population is restricted to males.
|
Mol Genet Metab
|
2011
|
0.83
|
|
19
|
Gastric parietal cell antibodies are associated with glutamic acid decarboxylase-65 antibodies and the HLA DQA1*0501-DQB1*0301 haplotype in Type 1 diabetes mellitus. Belgian Diabetes Registry.
|
Diabet Med
|
2000
|
0.83
|
|
20
|
Mutational and genetic origin of LDL receptor gene mutations detected in both Belgian and Dutch familial hypercholesterolemics.
|
Hum Genet
|
1997
|
0.82
|
|
21
|
Serum and erythrocyte magnesium levels in type I and type II diabetics.
|
Acta Diabetol Lat
|
1986
|
0.79
|
|
22
|
Dose-response of simvastatin in primary hypercholesterolemia.
|
J Cardiovasc Pharmacol
|
1994
|
0.78
|
|
23
|
Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes.
|
Diabetes Care
|
2000
|
0.78
|
|
24
|
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].
|
Rev Med Liege
|
2008
|
0.78
|
|
25
|
Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients.
|
Nephrol Dial Transplant
|
1996
|
0.77
|
|
26
|
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
|
Rev Med Liege
|
2012
|
0.77
|
|
27
|
New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome.
|
J Thromb Haemost
|
2006
|
0.77
|
|
28
|
Screening for genetic variants in BDNF that contribute to childhood obesity.
|
Pediatr Obes
|
2013
|
0.76
|
|
29
|
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].
|
Rev Med Liege
|
2010
|
0.76
|
|
30
|
Two novel frameshift mutations in the low density lipoprotein receptor gene generated by endogenous sequence-directed mechanisms.
|
Hum Genet
|
1995
|
0.76
|
|
31
|
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
|
Rev Med Liege
|
2007
|
0.76
|
|
32
|
Metabolic disregulation in obese adolescents with sleep-disordered breathing before and after weight loss.
|
Obesity (Silver Spring)
|
2013
|
0.76
|
|
33
|
Body fat, body fat distribution and the respiratory system: a "fat neck" syndrome?
|
Eur Respir J
|
1992
|
0.75
|
|
34
|
Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report.
|
J Diabetes Complications
|
2000
|
0.75
|
|
35
|
[Endocannabinoid system in the brain...and elsewhere].
|
Rev Med Liege
|
2008
|
0.75
|
|
36
|
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
|
Rev Med Liege
|
2008
|
0.75
|
|
37
|
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"].
|
Rev Med Liege
|
2011
|
0.75
|
|
38
|
A rare silent G to T mutation in exon 4 of the human low density lipoprotein receptor gene.
|
Clin Genet
|
1995
|
0.75
|
|
39
|
[Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study].
|
Rev Med Liege
|
2009
|
0.75
|
|
40
|
Influence of mebendazole administration on metabolic control in type 1 (insulin-dependent) diabetic patients.
|
Diabetologia
|
1985
|
0.75
|
|
41
|
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].
|
Rev Med Liege
|
2008
|
0.75
|
|
42
|
A case of malnutrition after biliopancreatic diversion for morbid obesity.
|
Int J Obes Relat Metab Disord
|
1993
|
0.75
|
|
43
|
Effects of smoking on lipid parameters during therapeutic weight loss.
|
Atherosclerosis
|
1986
|
0.75
|
|
44
|
[The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium].
|
Rev Med Liege
|
2005
|
0.75
|
|
45
|
The "endocrine" dysmetabolism of visceral obesity. Lessons from exercise research.
|
Eur J Med
|
1993
|
0.75
|
|
46
|
Common genetic variation in sFRP5 is associated with fat distribution in men.
|
Endocrine
|
2013
|
0.75
|
|
47
|
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
|
Rev Med Liege
|
2013
|
0.75
|
|
48
|
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].
|
Rev Med Liege
|
2010
|
0.75
|
|
49
|
Insulinotropic effect of different formula of very low calorie protein supplemented diets in obesity.
|
Acta Clin Belg
|
1987
|
0.75
|
|
50
|
Phenotypic expression and frequency of familial defective apolipoprotein B-100 in Belgian hypercholesterolemics.
|
Atherosclerosis
|
1994
|
0.75
|
|
51
|
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
|
Rev Med Liege
|
2013
|
0.75
|
|
52
|
Promising new approaches to the management of obesity.
|
Drugs
|
2000
|
0.75
|
|
53
|
Decreased diet-induced thermogenesis in gluteal-femoral obesity.
|
J Am Coll Nutr
|
1989
|
0.75
|
|
54
|
Perioperative parenteral nutrition in the stressed diabetic patient.
|
World J Surg
|
1986
|
0.75
|
|
55
|
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach].
|
Rev Med Liege
|
2005
|
0.75
|
|
56
|
Intronic mutations at splice junctions in the low-density lipoprotein receptor gene.
|
Mol Cell Probes
|
1999
|
0.75
|
|
57
|
No conclusive evidence for association of polymorphisms in the adiponectin receptor 1 gene, AdipoR1, with common obesity.
|
Endocrine
|
2012
|
0.75
|